Men who live alone have poor anticoagulation control: results from Danish registries.
Event: ESC Congress 2019
Topic: Oral Anticoagulation
Session: Atrial fibrillation and oral anticoagulation 3
High facility preference for rivaroxaban in atrial fibrillation increases risk of major bleeding compared to facility preference for apixaban
Event: ESC Congress 2019
Topic: Stroke Prevention
Session: Atrial fibrillation and oral anticoagulation 4
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin across subgroups by renal function: results from Danish registries
Event: ESC Congress 2019
Topic: Stroke in Atrial Fibrillation
Session: Prevention of thromboembolism and atrial remodelling in atrial fibrillation
Use of oral anticoagulation and association to outcomes in atrial fibrillation patients who develop chronic kidney disease: a nationwide cohort study
Event: ESC Congress 2018
Topic: Stroke Prevention
Session: Atrial fibrillation - Stroke prevention
Outcomes in vitamin K antagonist treated atrial fibrillation patients with stable international normalized ratios
Event: ESC Congress 2017
Topic: Atrial fibrillation (AF)
Session: Progress in stroke prevention in atrial fibrillation
Factors associated with quality of anticoagulation control in patients with atrial fibrillation and risk of stroke and bleeding
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: Are you still afraid about bleeding risk of antithrombotic therapy in atrial fibrillation?
Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function
Event: ESC Congress 2016
Topic: Atrial fibrillation (AF)
Session: Anticoagulation in atrial fibrillation II
ESC 365 is supported by
